Leukemia Virus Type 2 and HIV-1 in Individuals Coinfected with Human T Cell Retroviral Interference on STAT Activation

Human T cell leukemia virus (HTLV) type-2 is a human retrovirus whose infection has not been tightly linked to human diseases. However, the fairly high prevalence of this infection among HIV-1-positive individuals indicates the importance of better understanding the potential interference of HTLV-2 infection on HIV-1 infection and AIDS. We previously demonstrated that one signature of PBMC freshly derived from HIV-1-infected individuals is the constitutive activation of a C-terminal truncated STAT5 (STAT5 (cid:1) ). Therefore, we analyzed the potential activation of STATs in HTLV-2 monoinfected and HTLV-2/HIV-1 dually infected individuals. We observed that PBMC of HTLV-2-infected individuals do not show STAT activation unless they are cultivated ex vivo, in the absence of any mitogenic stimuli, for at least 8 h. The emergence of STAT activation, namely of STAT1, in culture was mostly related to the secretion of IFN- (cid:2) . Of note, this phenomenon is not only a characteristic feature of HTLV-2-infected individuals but also occurred with PBMC of HIV-1 (cid:3) individuals. Surprisingly, HTLV-2/HIV-1 coinfection resulted in low/absent STAT activation in vivo that paralleled a diminished secretion of IFN- (cid:2) after ex vivo cultivation. Our findings indicate that both HTLV-2 and HIV-1 infection prime T lymphocytes for STAT1 activation, but they also highlight an interference exerted by HTLV-2 on HIV-1-induced STAT1 activation. Although the nature of such a phenomenon is unclear at the present, these findings support the hypothesis that HTLV-2 may interfere with HIV-1 infection at multiple levels. The Journal of Immunology, 2002, 169: 4443–4449.

[1]  A. Minagar,et al.  Epidemiologic features of HTLV-II: serologic and molecular evidence. , 2002, Annals of epidemiology.

[2]  D. Birx,et al.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection , 2002, Nature Medicine.

[3]  A. Lazzarin,et al.  Expression and Activation of a C-Terminal Truncated Isoform of STAT5 (STAT5Δ) Following Interleukin 2 Administration or AZT Monotherapy in HIV-Infected Individuals , 2001 .

[4]  W. Leonard.  Role of Jak Kinases and STATs in Cytokine Signal Transduction , 2001, International journal of hematology.

[5]  C. Bogdan,et al.  The Production of IFN-γ by IL-12/IL-18-Activated Macrophages Requires STAT4 Signaling and Is Inhibited by IL-41 , 2001, The Journal of Immunology.

[6]  M. Kaplan,et al.  Spontaneous Production of C-C Chemokines by Individuals Infected with Human T Lymphotropic Virus Type II (HTLV-II) Alone and HTLV-II/HIV-1 Coinfected Individuals1 , 2000, The Journal of Immunology.

[7]  T. Kitamura,et al.  Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) in hematopoietic cells. , 2000, International journal of hematology.

[8]  A. Cimarelli,et al.  HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1alpha. , 2000, Blood.

[9]  D. Dube,et al.  HTLV-II-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. , 2000, The New England journal of medicine.

[10]  L. Ivashkiv,et al.  Jak-STAT signaling pathways in cells of the immune system. , 2000, Reviews in immunogenetics.

[11]  J. Rich,et al.  Long-term non-progression of HIV-1 in a patient coinfected with HTLV-II. , 1999, Diagnostic microbiology and infectious disease.

[12]  M. Salemi,et al.  The origin and evolution of human T-cell lymphotropic virus type II (HTLV-II) and the relationship with its replication strategy. , 1999, Gene.

[13]  M. Moroni,et al.  Human T-Lymphotropic Virus Type 2 (HTLV-2) Provirus in Circulating Cells of the Monocyte/Macrophage Lineage in Patients Dually Infected with Human Immunodeficiency Virus Type 1 and HTLV-2 and Having Predominantly Sensory Polyneuropathy , 1998, Journal of Virology.

[14]  L. Testolin,et al.  Positive Selection of Apoptosis-resistant Cells Correlates with Activation of Dominant-Negative STAT5* , 1998, The Journal of Biological Chemistry.

[15]  R. Lal,et al.  Down-regulation of interleukin-10 expression and production is associated with spontaneous proliferation by lymphocytes from human T lymphotropic virus type II-infected persons. , 1998, The Journal of infectious diseases.

[16]  W. Leonard,et al.  Human and Simian T-Cell Leukemia Viruses Type 2 (HTLV-2 and STLV-2pan-p) Transform T Cells Independently of Jak/STAT Activation , 1998, Journal of Virology.

[17]  M. Jücker,et al.  Carboxyl-Truncated STAT5β Is Generated by a Nucleus-Associated Serine Protease in Early Hematopoietic Progenitors , 1998 .

[18]  A. O’Garra,et al.  Cytokines induce the development of functionally heterogeneous T helper cell subsets. , 1998, Immunity.

[19]  C. Bovolenta,et al.  High Affinity Receptor for IgG (FcγRI/CD64) Gene and STAT Protein Binding to the IFN-γ Response Region (GRR) Are Regulated Differentially in Human Neutrophils and Monocytes by IL-10 , 1998, The Journal of Immunology.

[20]  M. Re,et al.  Human T-cell leukemia virus type II directly acts on CD34+ hematopoietic precursors by increasing their survival potential. envelope-associated HLA class II molecules reverse this effect. , 1998, Blood.

[21]  C. Schindler,et al.  Functionally distinct isoforms of STAT5 are generated by protein processing. , 1997, Immunity.

[22]  D. Vlahov,et al.  An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. , 1996, The Journal of infectious diseases.

[23]  A. Miyajima,et al.  Suppression of interleukin‐3‐induced gene expression by a C‐terminal truncated Stat5: role of Stat5 in proliferation. , 1996, The EMBO journal.

[24]  Hidehiro Takahashi,et al.  Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[25]  R. Lal,et al.  Spontaneous proliferation of memory (CD45RO+) and naive (CD45RO‐) subsets of CD4 cells and CD8 cells in human T lymphotropic virus (HTLV) infection: distinctive patterns for HTLV‐I versus HTLV‐II , 1995, Clinical and experimental immunology.

[26]  R. Lal,et al.  In vivo cellular tropism of human T-lymphotropic virus type II is not restricted to CD8+ cells. , 1995, Virology.

[27]  J. Goedert,et al.  Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency virus type 1 coinfection, among US intravenous drug users. , 1995, The Journal of infectious diseases.

[28]  A. Cimarelli,et al.  Cellular tropism of human T-cell leukemia virus type II is enlarged to B lymphocytes in patients with high proviral load. , 1995, Virology.

[29]  M. Clerici,et al.  The Th1-Th2 hypothesis of HIV infection: new insights. , 1994, Immunology today.

[30]  A. Fauci,et al.  Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. , 1994, Antiviral research.

[31]  B. Groner,et al.  Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. , 1994, The EMBO journal.

[32]  R. Lal,et al.  Spontaneous lymphocyte proliferation in human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infection: T-cell subset responses and their relationships to the presence of provirus and viral antigen production. , 1994, Clinical and diagnostic laboratory immunology.

[33]  A. Giannetti,et al.  Quantitation by competitive PCR of HIV-1 proviral DNA in epidermal Langerhans cells of HIV-infected patients. , 1994, Journal of acquired immune deficiency syndromes.

[34]  N. Binkin,et al.  HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. , 1993, Journal of acquired immune deficiency syndromes.

[35]  M. Clerici,et al.  A TH1-->TH2 switch is a critical step in the etiology of HIV infection. , 1993, Immunology today.

[36]  Hidehiro Takahashi,et al.  In vivo cellular tropism of human T cell leukemia virus type II (HTLV- II) , 1992, The Journal of experimental medicine.

[37]  B. Hjelle,et al.  Chronic neurodegenerative disease associated with HTLV-II infection , 1992, The Lancet.

[38]  R. Gallo.  Human retroviruses: a decade of discovery and link with human disease. , 1991, The Journal of infectious diseases.

[39]  E. Reinherz,et al.  The human interferon‐γ gene contains an inducible promoter that can be transactivated by tax I and II , 1991, European journal of immunology.

[40]  J. Goedert,et al.  HTLV-I/II seroprevalence and HIV/HTLV coinfection among U.S. intravenous drug users. , 1991, Journal of acquired immune deficiency syndromes.

[41]  F. Lori,et al.  HTLV-II infection in Italian drug abusers , 1990, The Lancet.

[42]  J. Williams,et al.  Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. , 1989, Oncogene.

[43]  W. Blattner,et al.  PROGRESSION TO AIDS IN HOMOSEXUAL MEN CO-INFECTED WITH HIV AND HTLV-I IN TRINIDAD , 1987, The Lancet.

[44]  A. Saxon,et al.  T-lymphocyte variant of hairy-cell leukemia. , 1978, Annals of internal medicine.